STAT1 and graft versus host disease: Subsequent experiments, disrupting JAK/STAT1 signaling by the use of T cells lacking STAT1, a Th1 specific TF responding to IFN-γ Receptor (IFNγR) signaling, reported ameliorated GVHD outcomes in a minor antigen-mismatched and fully-MHC mismatched GVHD model (155).